Tag: NSCLC
Pfizer’s LORBRENA achieves 60% five-year survival in ALK-positive lung cancer
Phase 3 CROWN trial shows 81% reduction in progression risk and 94% fewer brain metastases compared to XALKORI®
Roche gets FDA approval for Alecensa in early lung cancer
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence
AstraZeneca receives marketing permission for Durvalumab (ImfinziTM) in India
Durvalumab is the only immunotherapy approved for patients with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) and was granted US FDA ‘breakthrough therapy’ designation on July 31, 2017.....................